Table 1 The list of HIT compounds from screening.

From: Inhibition of DNMT3B expression in activated hepatic stellate cells overcomes chemoresistance in the tumor microenvironment of hepatocellular carcinoma

Compound name

Area (µm2)

Intensity

Analysis

Min

Max

Min

Max

Obeticholic acid

215,670

283,973

4794

2989

High priority

CHIR-99021

213,761

292,034

2911

5987

High priority

CHIR-98014

215,857

308,126

2862

5193

High priority

GW 4064

216,670

301,007

2879

4056

High priority

DORAMECTIN

218,339

275,305

3167

5108

Low priority

Ch 55

204,184

284,740

4334

8856

Low priority

BMS 649

203,834

266,669

4720

6491

Low priority

CD 1530

173,535

259,662

5233

7466

Low priority

TTNPB

234,690

281,054

5503

6795

Low priority

Bexarotene

243,349

282,992

5148

6681

Low priority

ABT 724 trihydrochloride

207,427

244,103

4640

6015

Inactive

Naproxen sodium

205,662

252,185

3121

5574

Inactive

Topiramate

200,229

232,065

3461

5389

Inactive

PIRACETAM

206,765

226,420

4398

6190

Inactive

Sulindac

192,002

235,173

4517

6055

Inactive

Bosutinib (SKI-606)

210,267

234,489

4879

13,636

Inactive

CP 673451

195,122

254,811

5966

19,603

Inactive

Ginkgolide B

206,227

232,355

4305

5776

Inactive

SB 239063

201,532

236,077

4530

6253

Inactive

Lonidamine

198,253

245,470

4339

5944

Inactive